4、会议时间： 证券代码：301520 证券简称：万邦医药 公告编号：2025-063 安徽万邦医药科技股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日召开第三届董事会第四次会议并决议，公司董事会定于 2026 年 1 月 14 日（星 期三）14:30 召开 2026 年第一次临时股东会，本次会议采取现场表决与网络投 票相结合的方式召开，现将有关事项通知如下： 一、本次股东会召开的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 （1）现场会议时间：2026年01月14日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年0 ...

证券代码：301520 证券简称：万邦医药 公告编号：2025-060 （一）逐项审议通过《关于修订和制定公司部分治理制度的议案》 为进一步完善公司治理结构，促进公司规范运作，根据《中华人民共和国公 司法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定， 结合公司的实际情况，公司董事会同意对公司部分治理制度进行修订及制定新制 度。逐项表决结果如下： 1、《关于修订<董事和高级管理人员持有和买卖本公司股票管理制度>的议案》 表决结果：5 票同意、0 票反对、0 票弃权。 2、《关于修订<董事和高级管理人员薪酬管理制度>的议案》 表决结果：5 票同意、0 票反对、0 票弃权。 安徽万邦医药科技股份有限公司 第三届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 安徽万邦医药科技股份有限公司（以下简称"公司"）第三届董事会第四次 会议于 2025 年 12 月 25 日在公司 2 楼会议室以现场结合通讯表决的方式召开， 会议 ...

安徽万邦医药科技股份有限公司 关于使用部分闲置募集资金（含超募资金）及闲置自有资金 购买现金管理产品到期赎回并继续购买现金管理产品的进 展公告 证券代码：301520 证券简称：万邦医药 公告编号：2025-059 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"或"万邦医药"）于 2024 年 12 月 26 日召开第二届董事会第十六次会议、第二届监事会第十次会议， 2025 年 1 月 15 日召开公司 2025 年第一次临时股东大会，审议通过了《关于调 整自有资金、闲置募集资金的现金管理额度及期限的议案》，同意公司将用于现 金管理的闲置自有资金额度调整至 7.2 亿元人民币（不超过），用于现金管理的 募集资金（含超募资金）调整至不超过人民币 3.8 亿元（含本数）及将募集资金 专户余额以协定存款方式存放，前述额度有效期为 2025 年第一次临时股东大会 审议通过之日起 12 个月，额度有效期内可循环滚动使用。保荐机构对此出具了 无异议的核查意见。 具 体 内 容 详 见 公 司 2024 年 12 月 31 ...

Core Viewpoint - Wanbang Medical (301520.SZ) aims to enhance its competitive edge by leveraging professional institutions and integrating resources through a partnership with Shihezi Longtai Equity Investment Management Partnership [1] Group 1: Investment Details - The company-controlled Hefei Qunxiang Qiming Enterprise Management Partnership (Limited Partnership) will invest 10 million yuan as a limited partner in the Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) [1] - The investment represents a subscription ratio of 12.987% in the partnership [1] Group 2: Investment Focus - The investment will target areas related to new drug research and development, medical device development, and other pharmaceutical sectors [1] - Key focus areas include emerging medical enterprises, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing R&D companies [1]

Group 1 - The core point of the article is that Wanbang Medical announced a strategic investment to enhance its competitive edge by participating in a partnership with a venture capital firm, committing 10 million yuan for a 12.99% stake in the fund [1] - Wanbang Medical's revenue composition for the year 2024 is entirely from the CRO industry, indicating a focused business model [1] - As of the report, Wanbang Medical has a market capitalization of 2.7 billion yuan [1] Group 2 - The article also highlights a significant growth in the new energy heavy truck sector, with November sales increasing by 178% year-on-year, indicating strong demand and supply challenges [1]

一、本次投资概述 为进一步满足安徽万邦医药科技股份有限公司（以下简称"公司"）业务布 局及未来发展需要，更好地借助专业机构的专业力量及资源优势，整合各方资源， 提高公司的综合竞争力，由公司控制的合肥群象齐鸣企业管理合伙企业（有限合 伙）（以下简称"合肥群象"）于 2025 年 12 月 22 日与石河子市隆泰股权投资 管理企业（有限合伙）等各方签署了《嘉兴隆峰创业投资合伙企业(有限合伙) 合伙协议》（以下简称"《合伙协议》"）及相关文件，合肥群象拟作为有限合 伙人以自有资金认缴出资 1,000 万元，参与认购嘉兴隆峰创业投资合伙企业(有 限合伙)（以下简称"合伙企业"）的基金份额，认缴比例为 12.987%。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 7 号——交易与关联交易》《安徽万邦医药科技股份有限公司章程》 和公司《对外投资管理制度》等相关规定，本次投资事项无需提交董事会和股东 会审议，不构成关联交易，也不构成重大资产重组。 二、专业投资机构基本情况 （一）基金管理人、普通合伙人、执行事务合伙人的基本信息 机构名称：石河子市隆泰股权投资管理合伙企业(有限合伙) 证 ...

Core Viewpoint - Wanbang Medical announced on an interactive platform that as of December 10, 2025, the number of shareholders is 7,945 [2] Company Summary - The company has a total of 7,945 shareholders as of the specified date [2]

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]

Core Insights - During the past week, 64 stocks had a turnover rate exceeding 100%, indicating high trading activity in the market [1] - Among these, Beilong Precision topped the list with a weekly turnover rate of 228.83%, while Jingchuang Electric also surpassed 200% [1] - The sectors with stocks having turnover rates over 100% predominantly include defense, machinery, and computer industries [1] - In terms of weekly price performance, stocks such as Zhaobiao Co., Aerospace Development, and Haixin Food saw significant gains, each exceeding 30% [1]

Core Viewpoint - The A-share market experienced a strong opening on December 1, with all three major indices rising, driven by significant inflows into large-cap stocks and various sectors such as smart speakers, MCU chips, and rare earths [1][2][4]. Market Performance - On December 1, the Shanghai Composite Index, Shenzhen Component Index, ChiNext Index, and other indices saw increases of 0.65%, 1.25%, 1.31%, and 1.52% respectively, with the Shanghai Composite Index surpassing 3910 points [1][2]. - The total market turnover reached 1.89 trillion yuan, an increase of 291.7 billion yuan from the previous trading day, indicating a significant increase in trading activity [2][4]. Sector Analysis - Key sectors that showed strong performance included smart speakers, MCU chips, ice and snow tourism, rare earths, and 6G technology, while lithium battery-related sectors experienced some adjustments [2][3]. - Among the major industries, non-ferrous metals, communication, and electronics led the gains, with increases of 2.85%, 2.81%, and 1.58% respectively [2][4]. Stock Contributions - Major contributors to the Shenzhen Component Index included Ningde Times, Zhongji Xuchuang, and ZTE, which collectively contributed 64.08 points, accounting for nearly 40% of the index's rise [2]. - In the ChiNext Index, Ningde Times and Zhongji Xuchuang were also significant contributors, accounting for over 90% of the index's increase [2]. Fund Flow - On December 1, the net inflow of funds into the Shanghai and Shenzhen markets exceeded 40 billion yuan, with large-cap stocks attracting significant investment [3][4]. - A total of 2321 stocks saw net inflows, while 2827 stocks experienced net outflows, indicating a preference for large-cap stocks [3][4]. Future Market Outlook - Analysts suggest that the current market conditions, including easing overseas disturbances and expectations of global liquidity, provide a solid foundation for a potential year-end rally [5]. - Historical trends indicate that growth and cyclical sectors are likely to perform well, with a focus on sectors such as aviation equipment and AI-related technologies [5].